NANOVIRICIDES, INC.
NNVCNYSE
$1.75
↓ -1.1%Jul 17 close · end-of-day
Price
1Y↑ +9.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$37.8M
Enterprise Value
$34.6M
P/E
—
P/S
—
P/B
4.1
EV/EBITDA
—
PEG
—
FCF Yield
-19.5%
Dividend Yield
—
Revenue (TTM)
$0.00
Net Income (TTM)
-$8.1M
Free Cash Flow (TTM)
-$7.4M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-88.4%
ROIC
-108.7%
Debt / Equity
—
Net Cash
$3.2M
Return 1Y
+6.7%
Company profile
NanoViricides, Inc. discovers, develops, and commercializes drugs for the treatment of viral infections. Company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction. Company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide.
- CEO
- Anil R. Diwan
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- Connecticut
- Website
- nanoviricides.com
Earnings
NNVC Q3 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00—
Diluted EPS-$0.09↓ -35.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$8.7M | -$8.1M | -$8.9M | -$8.5M | -$9.6M |
| Net income | -$8.8M | -$8.1M | -$8.6M | -$8.3M | -$9.5M |
| Diluted EPS | -$0.81 | -$0.70 | -$0.74 | -$0.70 | -$0.63 |
| Operating cash flow | -$8.2M | -$5.9M | -$5.7M | -$6.3M | -$8.5M |
| Free cash flow | -$8.5M | -$6.2M | -$5.8M | -$6.5M | -$8.5M |
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | — | — | — |
| Net margin | — | — | — | — | — |
| Line item | Q4 '24 | Q1 '24 | Q2 '24 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$2.4M | -$3.2M | -$2.1M | -$2.2M | -$2.1M | -$1.8M | -$2.2M | -$2.0M |
| Net income | -$2.4M | -$3.1M | -$2.0M | -$2.2M | -$2.1M | -$1.8M | -$2.2M | -$2.0M |
| Diluted EPS | -$0.19 | -$0.23 | -$0.14 | -$0.14 | -$0.12 | -$0.10 | -$0.11 | -$0.09 |
| Operating cash flow | -$1.5M | -$2.6M | -$2.2M | -$2.0M | -$1.7M | -$1.6M | -$2.0M | -$1.9M |
| Free cash flow | -$1.6M | -$2.6M | -$2.2M | -$2.0M | -$1.7M | -$1.7M | -$2.0M | -$1.9M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 6, 2026
- 14d agoNNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental Drug For Ebolastocktwits.com
- 14d agoAs the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congofinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.